biohaven: "rimegepant pivotal phase 3 trial results -- conference call.". of migraine. more than 4 million of them have at least 15 migraine days each month. even though many drugs prevent and treat these headaches,..

loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people..consider making a donation to support the coverage that shapes the face of berkeley.